Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
821-840 of 3,900 trials

Acute Myeloid Leukemia: Comparing Conditioning Regimens in Children

We are studying two different treatment plans for children with Acute Myeloid Leukemia undergoing stem cell transplants. Our goal is to find out which plan leads to better survival and fewer side effects.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Giant Cell Arteritis: Stopping Tocilizumab

We are comparing immediate versus gradual stopping of tocilizumab in patients with giant cell arteritis. The goal is to see which method helps prevent relapses and improves quality of life.

Giant Cell Arteritis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesRheumatology

Long-term Safety Study for Ciltacabtagene Autoleucel

We are following up with patients who received cilta-cel to learn about any long-term side effects and how well the treatment works over time. This study aims to improve our understanding of the treatment's safety and effectiveness.

Multiple Myeloma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Psilocybin for Cancer-Related Depression

We are studying whether a single dose of psilocybin can help improve mood in adults aged 20-80 with major depression after a cancer diagnosis. Participants will compare its effects to a lower dose to assess changes in depressive symptoms.

Malignant TumorsMajor Depressive Disorder6-12 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteOncologyPsychiatry

Metastatic Colorectal Cancer: LB-100 and Atezolizumab Study

We are investigating a new combination of medications for patients with metastatic colorectal cancer to see if it is safe and effective. This study aims to find the best dose and understand how well the treatment works.

Microsatellite Stable Colorectal Cancer>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Ceftazidime-Avibactam for Critically Ill Patients

We are studying the best dosing of ceftazidime-avibactam for critically ill patients on continuous renal replacement therapy. This research aims to improve treatment effectiveness and safety.

Ceftazidime-avibactam Therapy1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNephrology

Pulmonary Arterial Hypertension: Treprostinil Palmitil Inhalation Powder

We are studying the long-term safety and effects of an inhalation powder for people with pulmonary arterial hypertension. This research aims to see if it improves exercise capacity and overall health.

Pulmonary Arterial Hypertension1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Hereditary Ichthyosis: Injectable Gentamicin Study

We are studying whether injectable gentamicin can improve skin scaling and redness in people with hereditary ichthyosis. This trial aims to assess its effects on skin condition and overall quality of life.

Congenital Ichthyosis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesDermatology

Refractory Heart Failure: Dapagliflozin Study

We are investigating how Dapagliflozin may help patients with refractory heart failure eliminate sodium and manage fluid levels during peritoneal dialysis. This study aims to improve treatment options for these patients.

Refractory Heart Failure≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineNephrology

Immune Thrombocytopenia: Avatrombopag vs. Rituximab

We are comparing the effectiveness of Avatrombopag and Rituximab in adults with ITP who did not respond to corticosteroids. The study aims to see which treatment better improves health-related quality of life and reduces fatigue.

Immune Thrombocytopenia1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal Medicine

CALR-Mutated Myeloproliferative Neoplasms: JNJ-88549968 Study

We are testing a new T-cell redirecting antibody for patients with CALR-mutated myeloproliferative neoplasms. This study aims to evaluate its safety and potential effectiveness in treating this condition.

CALR-mutated Myeloproliferative Neoplasms>2 yearsSafety phase (I)HematologyOncology

Carcinoma of Unknown Primary: [18F]F-FAPI PET-CT Study

We are investigating whether [18F]F-FAPI PET-CT can help identify the primary tumor in patients with carcinoma of unknown primary. This study aims to improve diagnosis and treatment options for these patients.

Carcinoma of Unknown Primary>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Migraine in Adolescents: Rimegepant Study

We are investigating whether rimegepant can help prevent migraines in adolescents aged 12 to under 18 with chronic migraine. The study will also assess its safety and how it affects the use of other migraine treatments.

Chronic Migraine1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Spinal Muscular Atrophy: Risdiplam Study for Infants

We are investigating how the medication risdiplam works and its safety in infants with spinal muscular atrophy. This study aims to provide important insights into its use for this condition.

Spinal Muscular Atrophy1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Kidney Cancer: New Treatment Study

We are investigating a new treatment option for individuals diagnosed with kidney cancer. The goal is to see if this treatment can improve outcomes compared to standard care.

Metastatic Renal Cell Carcinoma with End-Stage Renal Disease>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Head and Neck Cancer: Ficlatuzumab and Cetuximab Study

We are investigating whether the combination of ficlatuzumab and cetuximab improves survival in adults with recurrent or metastatic HPV-negative head and neck cancer. This study compares the effects of this combination to a placebo treatment.

Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

Posaconazole for Young Children with Fungal Infections

We are studying how well Posaconazole works and its safety in children under 2 years old with invasive fungal infections. This research will help us understand its effects compared to older patients.

Fungal Infection3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPediatrics

Trastuzumab Deruxtecan (T-DXd) for Unresectable or Metastatic HER2-low Breast Cancer

We are studying the effects of T-DXd in patients with hormone receptor-negative and hormone receptor-positive HER2-low breast cancer. The goal is to see if it can improve treatment outcomes compared to current options.

Advanced Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Richter's Syndrome: M-CHOP with Mosunetuzumab

We are studying a new treatment combining mosunetuzumab with CHOP for patients with Richter's Syndrome who have not had therapy before. The aim is to evaluate its effectiveness and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

B-Cell Non-Hodgkin’s Lymphoma: Glofitamab and Obinutuzumab Study

We are studying the safety and effectiveness of Glofitamab alone and with Obinutuzumab in patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. This trial aims to find the best dose and understand how these treatments work together.

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology